Subjects receive regular medical therapy (budesonide/formoterol [Symbicort; AstraZeneca, Cambridge, UK] or fluticasone/salmeterol [Seretide; GlaxoSmithKline, Brentford, UK]) as usual while participating in this study, except that changing the asthma control medication is not allowed during this study. On the basis of regular therapy, patients with asthma randomly allocated will receive two different acupuncture treatments: puncture at acupoints on the lung meridian or acupoints on the heart meridian.
Symbicort
Manufactured by AstraZeneca
Sourced in United Kingdom
Symbicort is a combination of two active substances, budesonide and formoterol, in a single inhaler. Budesonide is a corticosteroid and formoterol is a long-acting beta2-adrenergic agonist. The product is indicated for the treatment of asthma in adults and adolescents 12 years and older.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using symbicort
1
Acupuncture for Asthma Control
2
Asthma Medication Patterns in Children
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The patient data were collected and recorded using a data collection form. The collected demographic data included age, sex, and ethnicity. The clinical data included disease duration, type of preventive medications, number of preventive medications, disease severity, and the presence of comorbidities.
The data collected regarding medications were based on the types of preventive medications prescribed to asthmatic children, with reference to the UKMMC’s Drug Formulary. Among the types of preventive medications collected from the pharmacy dispensing database were corticosteroids: budesonide (Pulmicort® [AstraZeneca, London, UK], Giona® Easyhaler [Orion Corp, Espoo, Finland]), beclomethasone dipropionate (Becotide® Evohaler [GlaxoSmithKline, Inc, Brentford, UK], Beclomet Easyhaler® [Orion Corp]), and ciclesonide (Alvesco® [Takeda Pharmaceuticals International GmbH, Zurich, Switzerland]); leukotriene receptor antagonist: montelukast (Singulair® [Merck and Co, Inc, Whitehouse Station, NJ, USA]); and combination therapy: fluticasone plus salmeterol (Seretide® [GlaxoSmithKline, Inc]), budesonide plus formoterol (Symbicort® [AstraZeneca]), ipratropium plus fenoterol (Berodual-N® [Boehringer Ingelheim Gmbh, Ingelheim, Germany]), and ipratropium plus salbutamol (Combivent® [Boehringer Ingelheim Gmbh]).
The data collected regarding medications were based on the types of preventive medications prescribed to asthmatic children, with reference to the UKMMC’s Drug Formulary. Among the types of preventive medications collected from the pharmacy dispensing database were corticosteroids: budesonide (Pulmicort® [AstraZeneca, London, UK], Giona® Easyhaler [Orion Corp, Espoo, Finland]), beclomethasone dipropionate (Becotide® Evohaler [GlaxoSmithKline, Inc, Brentford, UK], Beclomet Easyhaler® [Orion Corp]), and ciclesonide (Alvesco® [Takeda Pharmaceuticals International GmbH, Zurich, Switzerland]); leukotriene receptor antagonist: montelukast (Singulair® [Merck and Co, Inc, Whitehouse Station, NJ, USA]); and combination therapy: fluticasone plus salmeterol (Seretide® [GlaxoSmithKline, Inc]), budesonide plus formoterol (Symbicort® [AstraZeneca]), ipratropium plus fenoterol (Berodual-N® [Boehringer Ingelheim Gmbh, Ingelheim, Germany]), and ipratropium plus salbutamol (Combivent® [Boehringer Ingelheim Gmbh]).
3
Pooled Analysis of Budesonide COPD Trials
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This individual, patient-level, pooled analysis included all AstraZeneca-sponsored parallel-group, double-blind, randomized controlled trials of budesonide-containing treatments conducted before May 29, 2015 that met the following criteria: 1) >8 weeks’ duration, 2) ≥60 patients with COPD, 3) an inhaled budesonide treatment arm (ie, budesonide [Pulmicort, AstraZeneca] or budesonide/formoterol [Symbicort, AstraZeneca]), and 4) a non-budesonide-containing comparator treatment arm (ie, formoterol or placebo). Because this paper reports a pooled analysis of previous clinical trials ethical approval was obtained in the context of each trial, but not for this study.
4
Optimized Treatment for Asthma Control
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We optimized the treatment in accordance with the level of control [7 (link)]. The patients were using DPIs delivering a combination of budesonide and formoterol, either Symbicort (AstraZeneca, Lund, Sweden) or Alenia (Aché Laboratórios Farmacêuticos S.A., Guarulhos, Brazil); or DPIs or pMDIs containing fluticasone combined with salmeterol (Seretide; GlaxoSmithKline, Stevenage, UK), montelucaste (Montelair; Aché Laboratórios), oral prednisolone (generic), or omalizumab (Xolair; Novartis Biociências S.A., São Paulo, Brazil).
5
Asthma Treatment Cost Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We considered two different cost measures: the annual costs and the average of annual costs. Asthma severity was classified by the 2006 GINA guidelines [9] . Since 2008, Asthma Control Test (ACT) scores have been estimated and reported in the database. Risk factors were weight status (obese if body mass index (BMI) ⩾27 kg•m -2 , overweight if BMI 24-26.9 kg•m -2 , and normal weight if BMI <24 kg•m -2 ) and smoking status (current smokers, former smokers and nonsmokers). Asthma drugs used to treat patients under the programme included anti-inflammatory therapy and bronchodilators. Anti-inflammatory drugs included combination drugs (Seretide (GlaxoSmithKline, Brentford, UK) or its generic name fluticasone/ salmeterol, and Symbicort (AstraZeneca, London, UK) or budesonide/formoterol) and controller drugs (budesonide, fluticasone, beclomethasone and montelukast). Note that montelukast was classified into the controller group to be consistent with the practice in Singapore. Bronchodilators or reliever medications refer to inhaled salbutamol and oral theophylline.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!